Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIMINO.
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category D/X
Category C
Antibiotic
Antibiotic